Lumexa Imaging (NASDAQ:LMRI) Stock Bumped Up to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Lumexa Imaging (NASDAQ:LMRI) from a hold rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also recently commented on LMRI. UBS Group reissued a “strong-buy” rating on shares of Lumexa Imaging in a research report on Monday, September 28th. Raymond James Financial set a $17.00 price target on shares of Lumexa Imaging in a report on Monday, September 28th. KeyCorp started coverage on Lumexa Imaging in a report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. Finally, Barclays boosted their target price on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research note on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lumexa Imaging presently has a consensus rating of “Buy” and a consensus price target of $16.00.

Lumexa Imaging Price Performance

LMRI opened at $10.32 on Friday. The firm has a market capitalization of $991.44 million and a PE ratio of -21.06. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. The business’s 50-day moving average is $11.30 and its two-hundred day moving average is $10.30. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.03 by $0.17. The firm had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Research analysts anticipate that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its stake in shares of Lumexa Imaging by 506.9% during the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock worth $902,000 after buying an additional 66,763 shares during the period. Readystate Asset Management LP increased its position in shares of Lumexa Imaging by 11.5% in the 2nd quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock valued at $2,826,000 after acquiring an additional 25,778 shares during the period. AXQ Capital LP acquired a new position in shares of Lumexa Imaging in the 2nd quarter valued at $128,000. Bank of America Corp DE purchased a new position in Lumexa Imaging in the 2nd quarter worth $200,000. Finally, Jupiter Topco LLC acquired a new stake in Lumexa Imaging during the 2nd quarter worth about $24,269,000.

About Lumexa Imaging

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.